Destiny Pharma PLC
LSE:DEST
Destiny Pharma PLC
LSE:DEST
Price:
15.75 GBX
Market Closed
Updated:
Jun 1, 2024
Destiny Pharma PLC
Additional Paid In Capital
|
Destiny Pharma PLC
Additional Paid In Capital Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Destiny Pharma PLC
LSE:DEST
|
Additional Paid In Capital
£39.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Additional Paid In Capital
$987.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Additional Paid In Capital
$1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Additional Paid In Capital
$894.6m
|
CAGR 3-Years
42%
|
CAGR 5-Years
236%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Additional Paid In Capital
£1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Additional Paid In Capital
£179.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
See Also
What is Destiny Pharma PLC's Additional Paid In Capital?
Additional Paid In Capital
39.6m
GBP
39.6m
GBP
Based on the financial report for Dec 31, 2023, Destiny Pharma PLC's Additional Paid In Capital amounts to 39.6m GBP.
What is Destiny Pharma PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
18%
18%
Over the last year, the Additional Paid In Capital growth was 20%. The average annual Additional Paid In Capital growth rates for Destiny Pharma PLC have been 13% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
